Education and Training
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cilta-cel
Eligibility
Inclusion Criteria:
- Participants who have received at least one dose of cilta-cel in a Company-sponsored
clinical study
- Participants who have provided informed consent for this study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
Not Recruiting